Thomas Tillett – Cofounder and CEO of MBF Therapeutics, an immunotherapeutics company that has developed and patented an innovative, proprietary T-Max Precision™ DNA vaccine platform to deliver commercial protective vaccines that provide safe, durable, heterologous protection against endemic, emerging and re-emerging diseases of global concern to livestock and companion animals, with significant translational opportunities in human health.

Tom is the founder and Executive Director of Sustained Acts, a Christian non-profit focusing on sustainable projects in Africa, and serves on the Friends of Kijabe Hospital Board of Directors. Mr. Tillett was founder, and CEO of RHeoGene. As Rheo Gene CEO, he and his team created the RheoSwitch® Therapeutic System (RTS) that led to the first human clinical trial of a small molecule-induced gene regulation system.

In 2007, he completed the merger of RheoGene Inc. with Intrexon Corporation which has continued the development of RTS through various clinical trials for cancer and other important therapeutic indications. In April 2019 the FDA announced that the RheoSwitch Therapeutic System for glioma blastoma was approved for Fast Track designation. Mr. Tillett has served on the board of numerous non-profits including; the University of North Carolina General Alumni Association, Impact Thrift Stores, Chelten Church Elder Board, and the American School of Paris. He was also elected to the Hatboro-Horsham Hall of Fame in 2017.